1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: 011 (49) 30450536940.
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Increased expression of avian erythroblastosis virus E26 oncogene homolog 1 in World Health Organization grade 1 meningiomas is associated with an elevated risk of recurrence and is correlated with the expression of its target genes matrix metalloproteinase-2 and MMP-9
Article first published online: 7 AUG 2006
DOI: 10.1002/cncr.22130
Copyright © 2006 American Cancer Society
Additional Information
How to Cite
Okuducu, A. F., Zils, U., Michaelis, S. A. M., Mawrin, C. and von Deimling, A. (2006), Increased expression of avian erythroblastosis virus E26 oncogene homolog 1 in World Health Organization grade 1 meningiomas is associated with an elevated risk of recurrence and is correlated with the expression of its target genes matrix metalloproteinase-2 and MMP-9. Cancer, 107: 1365–1372. doi: 10.1002/cncr.22130
- ‡
Fax: 011 (49) 30450536940.
Publication History
- Issue published online: 1 SEP 2006
- Article first published online: 7 AUG 2006
- Manuscript Accepted: 22 MAY 2006
- Manuscript Received: 26 APR 2006
REFERENCES
- 1, , , , . Meningiomas. In: KleihuesP, CaveneeWK, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC Press; 2000: 174–186.
- 2, . Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas. Arch Pathol Lab Med. 1999; 123: 793–800.
- 3, , , et al. Lack of alkaline phosphatase activity predicts meningioma recurrence. Am J Clin Pathol. 2005; 124: 252–258.
- 4, , , . The hTERT-protein and Ki-67 labelling index in recurrent and non-recurrent meningiomas. Cell Prolif. 2005; 38: 3–12.
- 5, , , et al. Coexpression of hepatocyte growth factor/scatter factor (HGF/SF) and its receptor cMET predict recurrence of meningiomas. Cancer Lett. 2004; 213: 117–124.
- 6, , , et al. Correlation of clinical and biological parameters with peritumoral edema in meningioma. J Neurooncol. 2002; 60: 235–245.
- 7, , . Expression of matrix metalloproteinases 2 and 9 in meningiomas associated with different degrees of brain invasiveness and edema. J Neurosurg. 2001; 95: 839–844.
- 8, , , et al. Expression of matrix metalloproteinases and their inhibitors in human brain tumors. Clin Exp Metastasis. 1999; 17: 555–566.
- 9, , , , . Stromelysin-3 is expressed by aggressive meningiomas. Cancer. 2002; 94: 765–772.
- 10. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol. 2003; 200: 448–464.
- 11, , , . Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol. 2004; 48: 411–424.
- 12, , , . Recurrence of convexity meningiomas: tumor cells in the arachnoid membrane. Surg Neurol. 2001; 56: 228–235.
- 13, , , et al. Risk factors predicting recurrence in patients operated on for intracranial meningioma. A multivariate analysis. Acta Neurochir (Wien). 1999; 141: 921–932.
- 14, , , , . The transcription factor Ets-1 is expressed in human amniochorionic membranes and is up-regulated in term and preterm premature rupture of membranes. J Perinat Med. 2005; 33: 314–319.
- 15
- 16, . Ets target genes: past, present and future. Oncogene. 2000; 19: 6533–6548.
- 17. The ETS-domain transcription factor family. Nat Rev Mol Cell Biol. 2001; 2: 827–837.
- 18. Ets factors and regulation of the extracellular matrix. Oncogene. 2000; 19: 6464–6471.
- 19, , . Expression and purification of recombinant mouse Ets-1 transcription factor. Protein Expr Purif. 2001; 21: 492–499.
- 20, , , , , . A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/Type IV collagenase) using monoclonal antibodies. Clin Chim Acta. 1993; 221: 91–103.
- 21, , , . Inhibition of matrix metalloproteinase 9 activation by a specific monoclonal antibody. Hybridoma. 1993; 12: 349–363.
- 22, , , et al. Estrogen receptor analysis on biopsies and fine-needle aspirates from human breast carcinoma. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Am J Pathol. 1986; 125: 443–449.
- 23, , , et al. Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome. Am J Surg Pathol. 2001; 25: 1493–1500.
- 24, , , , . Expression of ets-1 transcription factor is correlated with penetrating tumor progression in patients with squamous cell carcinoma of the esophagus. Cancer. 2000; 89: 1670–1676.
- 25, , , , . Expression of the ets-1 proto-oncogene in human colorectal carcinoma. Mod Pathol. 2001; 14: 415–422.
- 26, . Ets-1 and integrin beta3 for lung metastasis from colorectal cancer. APMIS. 2002; 110: 347–353.
- 27, , , et al. Inactivation of Ets 1 transcription factor by a specific decoy strategy reduces rat C6 glioma cell proliferation and mmp-9 expression. Int J Mol Med. 2005; 15: 771–776.
- 28, , , , , . Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth. Oncogene. 2005; 24: 5384–5388.
- 29, , , et al. Immunohistochemical expression of Ets-1 transcription factor and the urokinase-type plasminogen activator is correlated with the malignant and invasive potential in meningiomas. Cancer. 2000; 89: 2292–2300.
- 30, , , , . Enhanced expression and activation of major matrix metalloproteinases in distinct topographic areas of invasive breast carcinomas. Int J Oncol. 2005; 26: 1203–1207.
- 31, , , , , . Association of ets-related transcriptional factor E1AF expression with tumour progression and overexpression of MMP-1 and matrilysin in human colorectal cancer. J Pathol. 2003; 200: 568–576.
- 32, , , et al. Clinical significance of matrix metalloproteinase-7 and Ets-1 gene expression in patients with lung cancer. J Surg Res. 2001; 101: 242–247.
- 33, , . Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas. Anticancer Res. 2003; 23: 3937–3944.
- 34, , , , . Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms. J Neurooncol. 2000; 46: 81–90.
- 35, , , , , . Matrix metalloproteinase-2 and matrix metalloproteinase-9 expressions correlate with the recurrence of intracranial meningiomas. J Neurooncol. 2004; 66: 29–37.
- 36, , . Expression of extracellular matrix markers in benign meningiomas. Neuropathology. 2003; 23: 275–281.
- 37, , , , . Invasive properties of serous human epithelial ovarian tumors are related to Ets-1, MMP-1 and MMP-9 expression. Int J Mol Med. 2001; 8: 149–154.
- 38, , , , . The Ets-1 transcription factor is up-regulated together with MMP 1 and MMP 9 in the stroma of pre-invasive breast cancer. J Pathol. 2001; 194: 43–50.
- 39, , , et al. Involvement of the Ets-1 gene in overexpression of matrilysin in human hepatocellular carcinoma. Cancer Res. 2000; 60: 6519–6525.
- 40, , , . Long-term outcome and growth rate of subtotally resected petroclival meningiomas: experience with 38 cases. Neurosurgery. 2000; 46: 567–574; discussion, 574–565.
- 41, , , , . Surgical management of petroclival meningiomas: defining resection goals based on risk of neurological morbidity and tumor recurrence rates in 137 patients. Neurosurgery. 2005; 56: 546–559; discussion, 546–559.
- 42, , , . Petroclival meningiomas: surgical experience in 109 cases. J Neurosurg. 1996; 84: 20–28.
- 43, , , et al. Meningiomas of the basal posterior fossa. Surgical experience in 80 cases. Neurocirugia (Astur). 2004; 15: 525–542.